To the full analysis
Genscript Biotech stock: growth
1548.HKGenscript Biotech reported $959.53M in revenue for fiscal 2025, up 61.4% on the prior year, up 19.7% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
26%
per year from 2013 to 2025, per share 22.8%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
42%
per year from 2013 to 2025, per share 38.4%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2013 | |
|---|---|---|---|
| Revenue | 19.7% | 27.2% | 26.0% |
| Revenue per share | 16.6% | 19.8% | 22.8% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | 34.0% | 42.0% |
| Free cash flow per share | no data | 26.3% | 38.4% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2013 | $60.1M | $6M | $3.61M |
| 2014 | $69.99M | $6.18M | $4.85M |
| 2015 | $86.71M | $17.5M | $12.93M |
| 2016 | $114.74M | $26.17M | $24.72M |
| 2017 | $152.65M | $26.12M | −$7.85M |
| 2018 | $231.02M | $21.22M | $236.82M |
| 2019 | $273.35M | −$96.91M | −$140.33M |
| 2020 | $390.85M | −$204.95M | −$272.97M |
| 2021 | $490.1M | −$358.71M | −$269.83M |
| 2022 | $625.7M | −$226.85M | −$336.41M |
| 2023 | $560.48M | −$95.48M | −$444.62M |
| 2024 | $594.49M | $2.96B | −$72.27M |
| 2025 | $959.53M | −$532.83M | $241.69M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 13 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = HK$7.8782)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 16 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.